No Data
Fufeng Pharmaceutical (601089.SH): Montmorillonite powder obtained pharmaceutical registration certificate.
Fuyuan Pharmaceutical (601089.SH) announced that recently, its wholly-owned subsidiary zhejiang Aisheng Pharmaceutical Co., Ltd. (...)
Fuyuan Pharmaceutical (601089.SH): Maoguoyunxiang alkaloid hydrochloride eye drops obtained the Notice of Approval for Clinical Trials of Drugs.
Fufeng Pharmaceutical (601089.SH) announced that the company recently received the approval and issuance of the National Medical Products Administration...
Beijing Fuyuan Pharmaceutical Co., Ltd. Report for the third quarter of 2024
Fufeng Pharmaceutical (601089.SH) released its performance for the first three quarters, with a net income of 0.401 billion yuan, a year-on-year increase of 5.59%.
Fuyuan Pharmaceutical (601089.SH) disclosed its third quarter report for 2024, achieving revenue of 25...
Fosun Pharma (601089.SH): The net income in the first three quarters was 0.401 billion yuan, a year-on-year increase of 5.59%.
Gelonghui October 24th | Fuyuan Pharmaceuticals (601089.SH) released the third quarter report for 2024, with the company's revenue in the first three quarters of 2.547 billion yuan, a year-on-year increase of 3.42%; net income attributable to shareholders of the listed company was 0.401 billion yuan, a year-on-year increase of 5.59%; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 0.38 billion yuan, a year-on-year increase of 3.29%; and the basic earnings per share was 0.85 yuan.
Fosun Pharma (601089.SH): The company did not repurchase shares in September.
格隆汇October 8th | Fuyuan Medicine (601089.SH) announced that in September 2024, the company did not repurchase shares. As of September 30, 2024, the company has repurchased a total of 12,000,000 shares through centralized bidding trading, with the repurchased shares accounting for approximately 2.50% of the total share capital of the company. The highest price traded was 15.59 yuan/share, the lowest price was 13.59 yuan/share, and the total amount paid was 176,169,816.92 yuan (excluding transaction costs).
No Data
No Data